As CAR-T Therapies Move Into Earlier Lines, Best Uses Begin To Come Into Focus

Yescarta, Breyanzi Second-Line LBCL Approvals Expected Soon

 
• By Mandy Jackson

Cost, logistics and safety could limit use of CAR-T therapies in first- and second-line treatment of hematologic malignancies, but for some patients there are clear benefits over standards of care.

Double escalator going up
CAR-T therapies are moving up from third-line or later into second-line and earlier settings • Source: Alamy

More from Clinical Trials

More from R&D